Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.
Identifieur interne : 004C06 ( Ncbi/Curation ); précédent : 004C05; suivant : 004C07Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.
Auteurs : K. Papp [Canada] ; H. Bachelez [France] ; A. Costanzo [Italie] ; P. Foley [Australie] ; M. Gooderham [Canada] ; P. Kaur [États-Unis] ; S. Philipp [Allemagne] ; L. Spelman [Australie] ; N. Zhang [États-Unis] ; B. Strober [États-Unis]Source :
- The British journal of dermatology [ 1365-2133 ] ; 2017.
Abstract
ABP 501, an FDA- and EMA-approved biosimilar, is highly similar to adalimumab in structure, function, and pharmacokinetics.
DOI: 10.1111/bjd.15857
PubMed: 28755394
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000939
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000936
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000936
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004C06
Links to Exploration step
pubmed:28755394Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.</title>
<author><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research and Probity Medical Research, Waterloo, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Clinical Research and Probity Medical Research, Waterloo, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bachelez, H" sort="Bachelez, H" uniqKey="Bachelez H" first="H" last="Bachelez">H. Bachelez</name>
<affiliation wicri:level="3"><nlm:affiliation>Sorbonne Paris Cité Université Paris Diderot, Department of Dermatology, AP-HP HP Hôpital Saint-Louis, INSERM U1163, Institut Imagine, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sorbonne Paris Cité Université Paris Diderot, Department of Dermatology, AP-HP HP Hôpital Saint-Louis, INSERM U1163, Institut Imagine, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Costanzo, A" sort="Costanzo, A" uniqKey="Costanzo A" first="A" last="Costanzo">A. Costanzo</name>
<affiliation wicri:level="1"><nlm:affiliation>Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano - Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano - Milan</wicri:regionArea>
<wicri:noRegion>Rozzano - Milan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Foley, P" sort="Foley, P" uniqKey="Foley P" first="P" last="Foley">P. Foley</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine (Dermatology), The University of Melbourne, St Vincent's Hospital Melbourne, Skin& Cancer Foundation Inc, and Probity Medical Research, Carlton, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Medicine (Dermatology), The University of Melbourne, St Vincent's Hospital Melbourne, Skin& Cancer Foundation Inc, and Probity Medical Research, Carlton</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gooderham, M" sort="Gooderham, M" uniqKey="Gooderham M" first="M" last="Gooderham">M. Gooderham</name>
<affiliation wicri:level="1"><nlm:affiliation>SKiN Centre for Dermatology and Probity Medical Research, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>SKiN Centre for Dermatology and Probity Medical Research, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kaur, P" sort="Kaur, P" uniqKey="Kaur P" first="P" last="Kaur">P. Kaur</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Philipp, S" sort="Philipp, S" uniqKey="Philipp S" first="S" last="Philipp">S. Philipp</name>
<affiliation wicri:level="3"><nlm:affiliation>Psoriasis Research and Treatment Center, University Hospital Charité, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Psoriasis Research and Treatment Center, University Hospital Charité, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spelman, L" sort="Spelman, L" uniqKey="Spelman L" first="L" last="Spelman">L. Spelman</name>
<affiliation wicri:level="1"><nlm:affiliation>Veracity Clinical Research and Probity Medical Research, Woolloongabba, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Veracity Clinical Research and Probity Medical Research, Woolloongabba, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhang, N" sort="Zhang, N" uniqKey="Zhang N" first="N" last="Zhang">N. Zhang</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strober, B" sort="Strober, B" uniqKey="Strober B" first="B" last="Strober">B. Strober</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Connecticut Health Center and Probity Medical Research, Farmington, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Connecticut Health Center and Probity Medical Research, Farmington, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28755394</idno>
<idno type="pmid">28755394</idno>
<idno type="doi">10.1111/bjd.15857</idno>
<idno type="wicri:Area/PubMed/Corpus">000939</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000939</idno>
<idno type="wicri:Area/PubMed/Curation">000936</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000936</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000936</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000936</idno>
<idno type="wicri:Area/Ncbi/Merge">004C06</idno>
<idno type="wicri:Area/Ncbi/Curation">004C06</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.</title>
<author><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research and Probity Medical Research, Waterloo, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Clinical Research and Probity Medical Research, Waterloo, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bachelez, H" sort="Bachelez, H" uniqKey="Bachelez H" first="H" last="Bachelez">H. Bachelez</name>
<affiliation wicri:level="3"><nlm:affiliation>Sorbonne Paris Cité Université Paris Diderot, Department of Dermatology, AP-HP HP Hôpital Saint-Louis, INSERM U1163, Institut Imagine, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sorbonne Paris Cité Université Paris Diderot, Department of Dermatology, AP-HP HP Hôpital Saint-Louis, INSERM U1163, Institut Imagine, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Costanzo, A" sort="Costanzo, A" uniqKey="Costanzo A" first="A" last="Costanzo">A. Costanzo</name>
<affiliation wicri:level="1"><nlm:affiliation>Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano - Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano - Milan</wicri:regionArea>
<wicri:noRegion>Rozzano - Milan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Foley, P" sort="Foley, P" uniqKey="Foley P" first="P" last="Foley">P. Foley</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine (Dermatology), The University of Melbourne, St Vincent's Hospital Melbourne, Skin& Cancer Foundation Inc, and Probity Medical Research, Carlton, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Medicine (Dermatology), The University of Melbourne, St Vincent's Hospital Melbourne, Skin& Cancer Foundation Inc, and Probity Medical Research, Carlton</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gooderham, M" sort="Gooderham, M" uniqKey="Gooderham M" first="M" last="Gooderham">M. Gooderham</name>
<affiliation wicri:level="1"><nlm:affiliation>SKiN Centre for Dermatology and Probity Medical Research, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>SKiN Centre for Dermatology and Probity Medical Research, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kaur, P" sort="Kaur, P" uniqKey="Kaur P" first="P" last="Kaur">P. Kaur</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Philipp, S" sort="Philipp, S" uniqKey="Philipp S" first="S" last="Philipp">S. Philipp</name>
<affiliation wicri:level="3"><nlm:affiliation>Psoriasis Research and Treatment Center, University Hospital Charité, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Psoriasis Research and Treatment Center, University Hospital Charité, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spelman, L" sort="Spelman, L" uniqKey="Spelman L" first="L" last="Spelman">L. Spelman</name>
<affiliation wicri:level="1"><nlm:affiliation>Veracity Clinical Research and Probity Medical Research, Woolloongabba, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Veracity Clinical Research and Probity Medical Research, Woolloongabba, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhang, N" sort="Zhang, N" uniqKey="Zhang N" first="N" last="Zhang">N. Zhang</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strober, B" sort="Strober, B" uniqKey="Strober B" first="B" last="Strober">B. Strober</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Connecticut Health Center and Probity Medical Research, Farmington, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Connecticut Health Center and Probity Medical Research, Farmington, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The British journal of dermatology</title>
<idno type="eISSN">1365-2133</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">ABP 501, an FDA- and EMA-approved biosimilar, is highly similar to adalimumab in structure, function, and pharmacokinetics.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004C06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:28755394 |texte= Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:28755394" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |